^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    topotecan

    i
    Other names: NK 211, NK-211, NK211, NSC 609699, SKF 104864
    Company:
    Generic mfg.
    Drug class:
    Topoisomerase I inhibitor
    Related drugs:
    1m
    A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer (clinicaltrials.gov)
    P3, N=404, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Initiation date: Apr 2026 --> Jul 2026
    Trial initiation date • Platinum resistant
    |
    FOLR1 ( Folate receptor alpha )
    |
    paclitaxel • topotecan • trastuzumab brengitecan (BL-M07D1)
    1m
    Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs (clinicaltrials.gov)
    P2, N=104, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> May 2027
    Trial completion date
    |
    berzosertib (M6620) • topotecan
    1m
    Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma (clinicaltrials.gov)
    P2, N=174, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Jan 2028 --> Feb 2027
    Trial completion date
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • mesna • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    2ms
    DAREONTM-9: DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy (clinicaltrials.gov)
    P1, N=69, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Jul 2027 --> Apr 2027
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    topotecan • obrixtamig (BI 764532)
    2ms
    FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer (clinicaltrials.gov)
    P3, N=1630, Recruiting, Eli Lilly and Company | N=1080 --> 1630 | Trial primary completion date: Apr 2028 --> Nov 2028
    Enrollment change • Trial primary completion date • Platinum sensitive • Platinum resistant
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • sofetabart mipitecan (LY4170156)
    2ms
    ZL-1310-003: A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer (2025-522818-23-00)
    P2/3, N=131, Not yet recruiting, Zai Lab (US) LLC
    New P2/3 trial
    |
    topotecan
    2ms
    TME/NIR Dual-Responsive Zinc-Based Targeted Nanoagonist for Multimodal Amplification of STING-Mediated Cancer Immunotherapy. (PubMed, Adv Sci (Weinh))
    The agonist combines cRGD peptide-targeted polydopamine-coated zeolitic imidazolate framework-8 with the photosensitizer indocyanine green and the chemotherapeutic drug topotecan...The mild photothermal therapy-induced immunogenic cell death promotes the initiation of antitumor immunity, while also enhancing the effectiveness of immune checkpoint blockade. In vivo studies show that cDZ@IP significantly inhibits primary and distant tumor growth and prevents lung metastasis, providing a promising strategy for STING pathway-targeted cancer immunotherapy.
    Journal
    |
    STING (stimulator of interferon response cGAMP interactor 1)
    |
    topotecan
    2ms
    NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov)
    P2, N=42, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Sep 2026 --> Mar 2026
    Trial completion • Trial completion date
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • dexrazoxane • Leukine (sargramostim)
    2ms
    A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) (clinicaltrials.gov)
    P3, N=686, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    gemcitabine • pemetrexed • irinotecan • vinorelbine tartrate • topotecan • Jiataile (sacituzumab tirumotecan) • Tivdak (tisotumab vedotin-tftv)
    2ms
    BCC023: Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma (clinicaltrials.gov)
    P2, N=406, Recruiting, Milton S. Hershey Medical Center | Not yet recruiting --> Recruiting
    Enrollment open • Pan tumor
    |
    cisplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • topotecan • Iwilfin (eflornithine)
    2ms
    A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=438, Active, not recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD276 (CD276 Molecule)
    |
    topotecan • tambotatug pelitecan (RG6919)
    3ms
    CLIP2 is a potential biomarker for platinum resistance and prognosis in ovarian cancer: a bioinformatics analysis. (PubMed, Transl Cancer Res)
    Drug sensitivity analysis revealed that high CLIP2 expression conferred resistance to platinum-based agents, topotecan, and gemcitabine, but heightened sensitivity to olaparib, cediranib, and pictilisib. Through bioinformatic analysis, this study proposes CLIP2 as a potential biomarker associated with platinum resistance and immune microenvironment patterns in ovarian cancer. These preliminary findings provide a basis for subsequent mechanistic studies and larger validation cohorts to confirm its clinical relevance in guiding immunotherapy and targeted treatment approaches.
    Journal • PARP Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule) • ADORA2A (Adenosine A2a Receptor) • CD48 (CD48 Molecule) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    Lynparza (olaparib) • gemcitabine • pictilisib (GDC-0941) • topotecan • Recentin (cediranib)